TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Trump Buys SpaceX Shares After Record IPO 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Tesla Raises Cybertruck Prices by $5,000 in US 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Add as a preferred source on Google
BOSTON, May 01, 2018 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2018.
Participants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 6639039. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 7:30 p.m. ET on May 8, 2018 through May 15, 2018 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 6639039.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The company’s lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at www.zafgen.com.
Media/Investor Relations Contacts:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792
Media
Krystle Gibbs
Ten Bridge Communications
[email protected]
508-479-6358
Investors
John Woolford
Westwicke Partners
[email protected]
443-213-0506
